A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer

Autor: Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, Niels Reinmuth, Martin Sebastian, Monika Serke, Cornelius Florian Waller, Michael Thomas, Jochen Eggert, Gerald Schmid-Bindert, Mathias Hoiczyk, Daniel Christian Christoph, Martin Kimmich, Burkhard Deuß, Stephanie Seifert, Swantje Held, Martin Schuler, Thomas Herold, Frank Breitenbuecher, Wilfried Ernst Erich Eberhardt

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Background: Pemetrexed and cisplatin is a first-line standard in non-squamous non-small-cell lung cancer without targetable mutations. It became the backbone of checkpoint-inhibitor–chemotherapy combinations. Single high doses of cisplatin pose tox

Externí odkaz: https://doaj.org/article/d242cd41cb214934942f7de020430e08

Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma

Autor: Filippo Rizzo, Diana Schaufler, Jens Panse, Matthias Scheffler, Kato Kambartel, Martin Metzenmacher, Judith Atz, Amin T. Turki, Christopher M. Hoffmann, Hannes Buchner, Mathias Hoiczyk, Daniel C. Christoph, Ivo Azeh

Publikováno v: Future oncology 17(30), 3965-3976 (2021). doi:10.2217/fon-2021-0424

Future oncology 17(30), 3965-3976 (2021). doi:10.2217/fon-2021-0424
Published by Future Medicine Ltd, London

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d68716ccd9695d9b11a957bafc27c4c0
https://pubmed.ncbi.nlm.nih.gov/34287064

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

Autor: Sebastian Bauer, Florian Grabellus, Peter Reichardt, E Bock, Daniel Pink, Mathias Hoiczyk, James Nagarajah, Martin Schuler, A. Pustowka, Susanne Grunewald, Annette Reichardt, Thomas Mühlenberg, Ralf A. Hilger, Max E. Scheulen, Marit Ahrens

Publikováno v: British Journal of Cancer

Background:Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a300eb851f80755434574259b663cdf
http://europepmc.org/articles/PMC3950855

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

Autor: Fred R. Hirsch, Daniel C. Christoph, Thomas Gauler, Julia D. Maltzman, Biftu Hassan, Murry W. Wynes, Jeremias Wohlschlaeger, Wilfried Eberhardt, Daniel J. O'Shannessy, Cindy Tran, Martin Schuler, Bernadette Reyna Asuncion, Mathias Hoiczyk

Publikováno v: Journal of Thoracic Oncology. 8:19-30

Introduction: Folate receptor alpha (FRA) regulates cellular uptake of folates and antifolates. Information about FRA protein expression in metastatic non–small-cell lung cancer (NSCLC) is limited. We investigated FRA as a biomarker for pemetrexed-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0e137aff7183e31f81d515952015be5
https://doi.org/10.1097/jto.0b013e31827628ff

A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)

Autor: Salih Zeki Guclu, Pablo Perez-Moreno, Elena Dorokhova, Caicun Zhou, Egbert F. Smit, Lada Mitchell, Martin Reck, Enriqueta Felip, Yi-Long Wu, Ulrich Freudensprung, Susan Grange, Radj Gervais, Mathias Hoiczyk, Jifeng Feng

Publikováno v: Smit, E F, Wu, Y-L, Gervais, R, Zhou, C, Felip, E, Feng, J, Guclu, S Z, Hoiczyk, M, Dorokhova, E, Freudensprung, U, Grange, S, Perez-Moreno, P D, Mitchell, L & Reck, M 2016, ' A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS) ', Lung Cancer, vol. 99, pp. 94-101 . https://doi.org/10.1016/j.lungcan.2016.06.019
Lung Cancer, 99, 94-101. Elsevier Ireland Ltd

Objectives Active smokers with non-small-cell lung cancer (NSCLC) have increased erlotinib metabolism versus non-smoking patients, which reduces exposure. Therefore, an increased erlotinib dose may be beneficial. The CurrentS study (NCT01183858) asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb59f654c8d085d306ac9bdb73b41d9
https://research.vumc.nl/en/publications/fcd4d439-eae1-4388-ad4c-f21670b147f0